top of page

MiRaDoR

A PROOF-OF-CONCEPT STUDY TO EVALUATE TREATMENTS' EFFICACY BY MONITORING MINIMAL RESIDUAL DISEASE USING ctDNA IN HR-POSITIVE/HER2-NEGATIVE EARLY BREAST CANCER POPULATION

https://clinicaltrials.gov/study/NCT05753124

HR+/HER2- early breast cancer with high risk of relapse

67

40 (possible 20 patient expansion cohort)

II

Spain, England, Brazil, Peru, Italy, France, Poland, Greece

Set-up

CLINICAL TRIAL DETAILS

THE PRIMARY OBJECTIVE IS TO EVALUATE THE EFFICACY IN TERMS OF RATE OF PATIENTS WITH A 90% DECREASE OR CLEARANCE IN BASELINE CTDNA AT THREE MONTHS AFTER RANDOMIZATION. IN ADDITION, THE STUDY WILL ASSESS THE EFFICACY IN TERMS OF THE RATE OF PATIENTS WITH A 90% DECREASE IN BASELINE CTDNA AT SIX, NINE AND TWELVE MONTHS, AS WELL AS ASSESS THE RATE OF PATIENTS WITH A 50% AND 70% DECREASE IN BASELINE CTDNA AT THREE, SIX, NINE AND TWELVE MONTHS.

TUMOR TYPE

PHASE

N

SITES

COUNTRY

STATUS

PRESS RELEASE

home_fondo_you_barra.jpg

SABCS 2023 - MiRaDor Press Release: https://www.medsir.org/post/press-release-mirador-at-san-antonio-breast-cancer-symposium

SCIENTIFIC IMPACT

home_fondo_you_barra.jpg

SABCS 2023 poster: https://www.medsir.org/_files/ugd/39f166_de276f3333484df980fb76febe239ced.pdf | SABCS 2023 lay language summary: https://www.medsir.org/_files/ugd/39f166_59d5f2e90f014bb4bc57da13e5a8a245.pdf

BLOG ARTICLES RELATED

home_fondo_you_barra.jpg

Highlights from San Antonio Breast Cancer Symposium 2024: Insights on locally advanced or metastatic HR-positive/HER2-negative breast cancer: https://www.medsir.org/post/highlights-from-san-antonio-breast-cancer-symposium-2024-insights-on-locally-advanced-or-metastatic | Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer: https://www.medsir.org/post/menarini-group-and-medsir-present-the-phase-iii-study-adela-a-new-therapeutic-strategy-for-advanced | Spotlight – NOBROLA trial for advanced triple-negative breast cancer: https://www.medsir.org/post/spotlight-nobrola-trial-for-advanced-triple-negative-breast-cancer

PHERGAIN SITES

home_fondo_you_barra.jpg
Hospital Universitario Clínico San Cecilio de Granada (Spain) | Hospital Clínic i Provincial de Barcelona (Spain) | Hospital Arnau de Vilanova de Valencia (Spain) | Complejo Hospitalario de Jaén (Spain) | Hospital General Universitario Dr. Balmis (Spain) | Hospital Universitario La Ribera, Alzira (Spain) | Hospital Virgen de los Lirios (Spain) | Hospital Marina Salud de Denia (Spain) | Hospital de Sagunto (Spain) | Hospital Universitario Virgen del Rocío (Spain) | Hospital Universitari Sant Joan de Reus (Spain) | Hospital Universitari Dexeus (Spain) | Hospital Universitario de Basurto (Spain) | Hospital Universitario Arnau de Vilanova de Lleida (Spain) | Hospital de Manises (Spain) | Barts Cancer Institute (England) | Centro de Câncer de Brasília (Brazil) | Belo Horizonte (Oncocentro) (Brazil)
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page